相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor-Infiltrating Lymphocytes and Response to Platinum in Triple-Negative Breast Cancer
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Determination of HLA-A, -C, -B,-DRB1 allele and haplotype frequency in Japanese population based on family study
N. Ikeda et al.
TISSUE ANTIGENS (2015)
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
Kayoko Waki et al.
CANCER SCIENCE (2014)
Personalized Peptide Vaccine for Treatment of Advanced Cancer
Tetsuro Sasada et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients
Kouichiro Kawano et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine
Masanori Noguchi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
Ryuji Takahashi et al.
CANCER SCIENCE (2013)
Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases
Satoko Matsueda et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2013)
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer
Yasuhiro Terazaki et al.
CANCER SCIENCE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen-A24 With Recurrent or Progressive Glioblastoma Multiforme
Mizuhiko Terasaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination
Masanori Noguchi et al.
CANCER BIOLOGY & THERAPY (2010)
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
Masanori Noguchi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients
Takashi Hattori et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients
Yamei Niu et al.
CANCER SCIENCE (2009)
Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer
Masanori Noguchi et al.
PROSTATE (2007)
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses
T Mine et al.
CLINICAL CANCER RESEARCH (2004)
New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization
N Komatsu et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2004)
分享论文
